DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
51 hedge funds and large institutions have $9.69M invested in DMK Pharmaceuticals Corporation Common Stock in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 13 closing their positions.
11% less funds holding
Funds holding: 57 → 51 (-6)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
58% less capital invested
Capital invested by funds: $22.8M → $9.69M (-$13.1M)
59% less call options, than puts
Call options by funds: $85K | Put options by funds: $209K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$862K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$243K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$135K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$63.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$3.41M |
| 2 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$3.36M |
| 3 |
Barclays
London,
United Kingdom
|
-$364K |
| 4 |
Millennium Management
New York
|
-$194K |
| 5 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
-$162K |
DMK Hedge Fund Activity: Q2 2019 in Review
51 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2019, worth a combined $9.69M — down 58% from $22.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of DMK and 8 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Morgan Stanley, adding an estimated $862K. The largest seller was First Manhattan, cutting an estimated $3.41M.
- 51 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2019, down from 57 in Q1 2019.
- Funds reported $9.69M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2019, down 58% quarter-over-quarter.
- 8 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2019 and 13 closed out, a net change of -5 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2019 was Morgan Stanley, an estimated $862K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2019 was First Manhattan, an estimated $3.41M sold.
Based on aggregated 13F filings for Q2 2019.